
Cabaletta Bio (CABA) Earnings Dates & Reports
Cabaletta Bio (CABA) Most Recent Earnings
Report Date
Period EndingQ3 2025
Est. EPS-$0.47
Actual EPS-$0.44
EarningsBeat
Cabaletta Bio (CABA) Earnings
View the latest Cabaletta Bio (CABA) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Cabaletta Bio (CABA)
Order type
Buy in
Order amount
Est. shares
0 shares
Cabaletta Bio (CABA) Earnings per Share (EPS) History
Signup for full accessBrowse free
Cabaletta Bio (CABA) Latest Earnings
The value each CABA share was expected to gain vs. the value each share gained.
Cabaletta Bio (CABA) reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of -$0.44. This exceeded analysts' expectations of -$0.47 by 6.38%, marking a Beat.
For comparison, Cabaletta Bio reported EPS of -$0.62 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.46.
Cabaletta Bio (CABA) Earnings History
Cabaletta Bio (CABA) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Cabaletta Bio’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Cabaletta Bio (CABA) Earnings FAQs
Cabaletta Bio (CABA) last reported earnings on Nov 10, 2025 for Q3 2025, posting an EPS of -$0.44, which Beat the estimate of -$0.47 by 6.38%.
For Q3 2025, Cabaletta Bio (CABA) reported an EPS of -$0.44, exceeding analysts' estimate of -$0.47 by 6.38%.
For Q3 2025, Cabaletta Bio (CABA) Beat expectations with an actual EPS of -$0.44 vs. an estimated EPS of -$0.47.
Following the last earnings report on Nov 10, 2025, Cabaletta Bio (CABA)'s stock price moved — from — to —.
The next Cabaletta Bio (CABA) earnings call is scheduled for Mar. 30, 2026, where executives will discuss financial results and outlook.